Employees: 4,493
Size Menicon (7780.T) is a Japan Health Care company (Medical Specialties) with a market value of $944M, the 766th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,973 on 18 Nov 2026.
Performance Over six months the shares gained 26.5%, against -13.6% for the median peer and -1.4% for the Japan market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue grew 5.6% over the last twelve months (peer median +8.4%); the operating margin is 8.7% (peer median 9.6%).
Valuation It trades at 20.9× forward earnings against a peer median of 19.9× (8th most expensive of 16).
Capital Return on invested capital runs 0.2 points above its cost of capital (5.2% WACC).
Next results Next results expected around 12 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥129B | ¥126B | ¥121B | ¥116B | ¥110B |
| Revenue growth | — | +3% | +5% | +5% | — |
| Gross profit | ¥69.2B | ¥67.6B | ¥65.1B | ¥61.0B | ¥58.5B |
| EBITDA | ¥22.5B | ¥21.1B | ¥18.5B | ¥16.9B | ¥19.5B |
| Net income | ¥6.34B | ¥5.92B | ¥5.60B | ¥4.54B | ¥7.38B |
| Free cash flow | n/a | -¥3.37B | -¥77.0M | -¥8.24B | ¥1.31B |
| Capital expenditure | n/a | ¥16.5B | ¥17.5B | ¥21.3B | ¥13.0B |
| Total debt | ¥78.1B | ¥74.2B | ¥75.1B | ¥70.8B | ¥53.6B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 7780.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.6% | -7.2% | 4th highest of 21 |
| 6-month return | +26.5% | -13.6% | 4th highest of 21 |
| Distance from 52-week high | -5.4% | -35.6% | highest of 21 |
| Revenue growth (TTM) | +5.6% | +8.4% | 10th lowest of 21 |
| Operating margin | 8.7% | 9.6% | 10th lowest of 21 |
| Forward P/E | 20.9× | 19.9× | 8th most expensive of 16 |
| ROIC minus cost of capital | +0.2 pp | +2.8 pp | 8th lowest of 20 |
| EV / EBITDA | 8.8× | 10.3× | 4th cheapest of 10 |
| Net debt / EBITDA | 2.1× | 0.3× | 3rd most indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Menicon 7780.T | Japan | $944M | +26% | +6% | 9% | 20.9× | n/a | n/a |
| L&C BIO 290650.KS | South Korea | $943M | -37% | +65% | 20% | n/a | 32.6% | +21.0% |
| Safilo SFL.MI | Italy | $953M | +42% | -4% | 9% | 15.8× | 1.3% | +4.7% |
| JINS 3046.T | Japan | $963M | -8% | +14% | 10% | 18.7× | -6.1% | +11.7% |
| Mani 7730.T | Japan | $965M | -7% | +10% | 30% | 19.9× | 3.3% | +13.9% |
| Kuros Biosciences KURN.SW | Switzerland | $907M | -12% | +41% | 6% | 70.5× | n/a | n/a |
| INKON Life Technology 300143.SZ | China | $985M | -23% | +22% | 12% | 50.3× | 10.7% | +12.9% |
| Artivion AORT | United States | $905M | -18% | +14% | 5% | 383.6× | n/a | n/a |
| Ceribell CBLL | United States | $995M | +42% | +31% | -70% | n/a | n/a | n/a |
| Bioventus BVS | United States | $895M | -3% | +4% | 10% | 13.0× | 7.5% | +12.1% |
| Aidite (Qinhuangdao) Technology 301580.SZ | China | $888M | -12% | +17% | 18% | 26.2× | 19.3% | +23.3% |
| Edan Instruments 300206.SZ | China | $1.00B | -19% | +14% | 17% | 18.0× | 6.9% | -2.9% |
| Shenzhen YHLO Biotech 688575.SS | China | $882M | -16% | +3% | 12% | 30.7× | 2.0% | +12.7% |
| Amoy Diagnostics 300685.SZ | China | $1.01B | -15% | +7% | 34% | 19.3× | 4.9% | +10.4% |
| Hangzhou Biotest Biotech 688767.SS | China | $878M | -12% | -4% | 3% | 37.0× | n/a | n/a |
| Xiangyu Medical 688626.SS | China | $877M | -38% | 0% | 4% | 56.2× | n/a | n/a |
| PHC 6523.T | Japan | $1.02B | +34% | +3% | 8% | 7.5× | -4.0% | +3.5% |
| Tinavi Medical Technologies 688277.SS | China | $872M | -36% | -2% | -59% | n/a | n/a | n/a |
| Inno Laser Technology 301021.SZ | China | $1.03B | -33% | +17% | 9% | n/a | 50.8% | +8.6% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.03B | -26% | -11% | -33% | n/a | n/a | n/a |
| Eckert & Ziegler EUZ.DE | Germany | $1.03B | -2% | +4% | 26% | 18.5× | 7.7% | +12.1% |